Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
Antiepileptic Drug Trials XIV 2017 Conference in Aventura, Florida on May 19th, 2017. View Presentation
9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.
9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016, San Diego, CA Associate Professor Stephen Macfarlane, FRANZCP View Presentation
Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease
World Parkinson Congress 2016, Portland, OR V. Francardo, F. Bez, J. Sprouse, C. Missling, M.A. Cenci View Poster
Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.
Alzheimer’s Association International Conference 2016, Toronto, Canada Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Christopher U. Missling View Poster
ANAVEX 2‐73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology.
2016 Rett Syndrome Symposium, Itasca, IL N. Rebowe, J. Sprouse, D. Brunner, P. Kabitzke, L. Velisek, M. Benson, J. Veliskova, C. Missling View Presentation
Sigma-1 Receptor Agonists as Potential Treatment Options for Autism Spectrum Disorders: Pre-clinical Studies with ANAVEX 2-73 in a Fragile X Model.
Gordon Research Conference for Fragile X and Autism-Related Disorders, Mount Snow, VT Patricia Cogram, Daniel Klamer, Nell Rebowe, Jeffrey Sprouse, Christopher U. Missling View Poster
14th International Symposium on Advances in Alzheimer Therapy, Athens, Greece Christopher U. Missling, PhD View Presentation
2016 Epilepsy Pipeline Conference, San Francisco, California Christopher U. Missling, PhD View Presentation
Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.
ACTRIMS Forum 2016, New Orleans, Louisiana Robert P. Lisak M.D., Liljana Nedelkoska, Joyce A. Benjamins, Ph.D., Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan View Poster
New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.
Alzheimer’s Association International Conference 2016, Toronto, Canada Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Anastasios Zografidis, Christopher U. Missling View Poster
The American Epilepsy Society Annual Meeting 2015, Philadelphia, PA Nell Rebowe, Christopher U. Missling View Poster